Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal

Search Medical Condition
Please enter condition
Please choose location

Myelofibrosis Clinical Trials

A listing of Myelofibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (39) clinical trials

Study of the JAK Inhibitor INCB018424 tablet administered orally to subjects with primary myelofibrosis, post-polycythemia vera-myelofibrosis or post-essential thrombocythemia-myelofibrosis Patient Inclusion Criteria: 18 + years of age, diagnosis of PMF or PPV-MF, either resistant or refractory to, intolerant of, or in the investigator's opinion not candidates for available therapy, must ...

Phase

People with myelofibrosis are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

People with Myelofibrosis are asked to participate in a research study being conducted by Montefiore Medical Center..

Phase N/A

This is a prospective, longitudinal, non-interventional study in an adult population (age ≥ 18 years) of men and women who have been diagnosed with select subcategories of either MF or ET. Patients will be enrolled over approximately 24 months and observed for a minimum of 36 months from enrollment.

Phase

A research study is evaluating an investigational medication for patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis This research study may be an option if you: • Are at least 18 years of age • Have been diagnosed with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia ...

Phase N/A

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

PRIMARY OBJECTIVES: I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF). SECONDARY OBJECTIVES: I. Determine preliminary efficacy of alisertib in both populations. TERCIARY OBJECTIVES: I. Describe pharmacodynamics (PD) effects of alisertib in peripheral blood and/or bone marrow samples. II. ...

Phase N/A

Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF) Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Study Drug Administration: If you are found to be eligible to take part in this study, you will take LCL161 by mouth on Days 1, 8, 15, and 22 of each cycle, +/- 3 days. You will fast for 2 hours before and 2 hours after taking LCL161. This means ...

Phase

A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia Myelodysplastic Syndrome Myelodysplastic/Myeloproliferative Neoplasms and Myelofibrosis

Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofribrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Phase

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1 to oral single-agent glasdegib versus placebo in 201 patients ...

Phase

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis

This is a phase Ib study with the primary purpose is to estimate the MTD and/or RDE for the triple combination of PIM447, formerly LGH447, plus ruxolitinib and LEE011 as well as for the doublets, PIM447 plus ruxolitinib, and LEE011 plus ruxolitinib, in patients with myelofibrosis (MF). Each regimen will ...

Phase